Sponsors, CROs and academic research teams choosing an eCOA platform for a regulated clinical trial.
Scope Electronic clinical outcome assessment (eCOA) platforms that capture patient-reported (ePRO), clinician-reported, observer-reported and performance outcomes in regulated clinical trials, as a sponsor, CRO or academic research team would shortlist them.
These notes describe the products in the eCOA guide.
Medidata eCOA
Best for
Large sponsors and CROs that already run Rave EDC and want eCOA in the same platform
What to consider
Medidata eCOA lists 2,500+ COAs, 200+ languages and dialects and 1,600+ studies, and data flows straight into Rave EDC. Study builders can configure it in Medidata Designer, with an average study start of 8 weeks. Prices are not published.
Sponsors that want eCOA, IRT and eConsent from one vendor across many languages
What to consider
YPrime covers 250+ languages and 100+ countries and integrates eCOA with its own IRT and eConsent. It documents Part 11 and GxP compliance and nearly 1,000 studies, but no approval counts, and its ISO 27001 certification is still in progress. Builds are vendor-led and prices are not published.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Medidata eCOA vs YPrime (eCOA): category feature evidence and sources. Products are not ranked.
Category feature
Medidata eCOA
YPrime
Validated instrument library and licensingFeature definitions
Supported
A library of outcome-assessment instruments is documented.
Extended support
A validated or instrument-author-approved library plus managed instrument licensing are documented.
Medidata eCOA
Extended support
2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.
Pre-validated libraries and licensing relationships are stated; managed licensing is not established.
Regulatory compliance and track recordFeature definitions
Supported
Relevant trial or security controls are stated.
Extended support
Relevant trial controls plus a public ISO/SOC certificate or audit report are documented; a certification claim or logo alone is insufficient.
Medidata eCOA
Supported
Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.
BYOD and provisioned capture are documented with wearables, glucometers and sensors.
Time to launch and self-service buildFeature definitions
Supported
A study build process, self-service builder or launch timeframe is documented.
Extended support
Study teams can configure the study themselves, with a stated build or launch timeframe.
Medidata eCOA
Extended support
Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.
Vendor-delivered builds are described; a self-service designer is not published.
Published pricing and termsFeature definitions
Supported
A production pricing basis, model or contract terms beyond a sales contact are published.
Extended support
Numerical production prices or a free production option with its conditions are published.
Medidata eCOA
Supported
No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.